1-7 of 7
Mary L Kwok, MD
Close
Sort by
Journal Articles

Treatment of High Risk (HR) Smoldering Multiple Myeloma (SMM) with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed By Lenalidomide Maintenance (-R): A Phase 2 Clinical and Correlative Study

Dickran Kazandjian, MD, Elizabeth Hill, MD, Candis Morrison, CNP, PhD, Alexander Dew, DO, MS, Neha Korde, MD, Sham Mailankody, MBBS, Elisabet E. Manasanch, MD, Mary L. Kwok, MD, Manisha Bhutani, MD, Nishant Tageja, MD, Yong Zhang, PhD, Ashley Carpenter, RN, Monica Epstein, RN, Michael Emanuel, BSN, RN, Crystal Lu, PharmD, BCOP, Raul C. Braylan, MD, Katherine R. Calvo, MD PhD, Peter Choyke, MD, Alina Dulau-Florea, MD, Esther Mena, MD, Liza Lindenberg, MD, Irina Maric, MD MSci, Nisha Patel, DO, Maryalice Stetler-Stevenson, MD PhD, Hao-Wei Wang, MD PhD, Constance M. Yuan, MD PhD, Seth M. Steinberg, PhD, William D. Figg, PhD, Mark Roschewski, MD, Ola Landgren, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 43–45.
https://doi.org/10.1182/blood-2020-136148
Published: 2020
Journal Articles

A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term Deep Remissions and Prolonged Progression-Free Duration Regardless of Age or Cytogenetic Risk after 5 Years of Follow up

Dickran Kazandjian, MD, Neha Korde, MD, Sham Mailankody, MBBS, Yong Zhang, PhD, Jennifer Hsu, RN, Elizabeth Hill, MD, Candis Morrison, CNP, PhD, Sneha Divakarla, MHA, Mary L. Kwok, MD, Elisabet E. Manasanch, MD, Manisha Bhutani, MD, Nishant Tageja, MD, Pallavi Galera, Alina Dulau-Florea, MD, Dalia Salem, MD, Esther Gonzalez, MD, Liza Lindenberg, MD, Irina Maric, MD MSci, Katherine R. Calvo, MD PhD, Raul C. Braylan, MD, Constance Yuan, MD PhD, Wyndham H. Wilson, MD PhD, Peter Choyke, MD, Maryalice Stetler-Stevenson, MD PhD, Seth M. Steinberg, PhD, William Figg, PharmD, Mark Roschewski, MD, Ola Landgren, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1957.
https://doi.org/10.1182/blood-2018-99-111712
Published: 2018
Journal Articles

Sustained High Rates of Complete Response and Minimal Residual Disease Negativity after 8 Cycles of Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (DEX) Followed By 2 Years of Lenalidomide Maintenance (CRd-R) in Patients with High-Risk Smoldering Multiple Myeloma: Updated Results of Clinical and Correlative Phase 2 Study

Dickran Kazandjian, MD, Neha S Korde, MD, Mark Roschewski, MD, Sham Mailankody, MD, Candis Morrison, RN, PhD, Elisabet E. Manasanch, MD, Mary L Kwok, MD, Nishant Tageja, MD, Manisha Bhutani, MD, Adriana Zingone, PhD, Rene Costello, Yong Zhang, PhD, Marcia Mulquin, Liz Lamping, Ashley Carpenter, Brenda Roberson, Irina Maric, MD, Katherine R. Calvo, MD PhD, Raul C Braylan, MD, Constance M. Yuan, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Diane C. Arthur, MD, Liza Lindenberg, Karen A. Kurdziel, MD, Peter Choyke, Seth M. Steinberg, PhD, William Figg, Wyndham H. Wilson, MD PhD, Ola Landgren, MD PhD
Journal: Blood
Blood (2016) 128 (22): 3339.
https://doi.org/10.1182/blood.V128.22.3339.3339
Published: 2016
Journal Articles

Sustained Minimal Residual Disease Negativity in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (DEX) Followed By 2 Years of Lenalidomide Maintenance (CRd-R): Updated Results of a Phase 2 Study

Dickran Kazandjian, MD, Neha S Korde, MD, Mark Roschewski, MD, Sham Mailankody, MD, Candis Morrison, RN, PhD, Elisabet E. Manasanch, MD, Mary L Kwok, MD, Nishant Tageja, MD, Manisha Bhutani, MD, Adriana Zingone, PhD, Rene Costello, Yong Zhang, PhD, Marcia Mulquin, Liz Lamping, Ashley Carpenter, Brenda Roberson, Irina Maric, MD, Katherine R. Calvo, MD PhD, Raul C Braylan, MD, Constance M. Yuan, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Diane C. Arthur, MD, Liza Lindenberg, Karen A. Kurdziel, MD, Peter Choyke, Seth M. Steinberg, PhD, William Figg, Wyndham H. Wilson, MD PhD, Ola Landgren, MD PhD
Journal: Blood
Blood (2016) 128 (22): 4527.
https://doi.org/10.1182/blood.V128.22.4527.4527
Published: 2016
Journal Articles

Minimal Residual Disease (MRD) Testing in Newly Diagnosed Multiple myeloma (MM) Patients: A Prospective Head-to-Head Assessment of Cell-Based, Molecular, and Molecular-Imaging Modalities

Neha Korde, MD, Sham Mailankody, MD, Mark Roschewski, MD, Malek Faham, Chitra Kotwaliwale, Martin Moorhead, PhD, Mary L Kwok, MD, Elisabet E. Manasanch, MD, Manisha Bhutani, MD, Nishant Tageja, MD, Dickran Kazandjian, MD, Rene Costello, Yong Zhang, MD PhD, Adriana Zingone, MD PhD, Debbie Burton, Marcia Mulquin, RN, Ashley Carpenter, RN, Diamond Zuchlinski, RN, Elizabeth Lamping, George Carter, PA, Candis Morrison, Karen Kurdziel, MD, Maria Lindenberg, MD, Roger Kurlander, MD, Irina Maric, MD, Katherine R. Calvo, MD, PhD, Raul C Braylan, MD, Constance Yuan, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Diane C Arthur, MD, Seth M. Steinberg, PhD, William D Figg, PharmD, Peter Choyke, MD, Ola Landgren, MD PhD
Journal: Blood
Blood (2014) 124 (21): 2105.
https://doi.org/10.1182/blood.V124.21.2105.2105
Published: 2014
Journal Articles

Phase II Clinical and Correlative Study Of Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Extended Dosing (CRD-R) Induces High Rates Of MRD Negativity In Newly Diagnosed Multiple Myeloma (MM) Patients

Neha Korde, MD, Adriana Zingone, MD, PhD, Mary L Kwok, MD, Elisabet E. Manasanch, MD, Manisha Bhutani, MD, Nishant Tageja, MD, Dickran Kazandjian, MD, Sham Mailankody, MD, Rene Costello, Yong Zhang, PhD, Debra Burton, George Carter, PA, Peter Wu, Marcia Mulquin, RN, Diamond Zuchlinski, RN, Irina Maric, MD, Katherine R Calvo, MD, PhD, Raul C. Braylan, Mark Roschewski, MD, Constance Yuan, MD, PhD, Maryalice Stetler-Stevenson, MD, PhD, Diane C Arthur, M.D., Liza Lindenberg, MD, Karen Kurdziel, MD, Pete Choyke, MD, Seth M. Steinberg, PhD, Ola Landgren, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 538.
https://doi.org/10.1182/blood.V122.21.538.538
Published: 2013
Journal Articles

Altered Plasma Cell Characteristics in Smoldering Myeloma and MGUS Patients with Preceding Immune-Related Conditions

Mary L Kwok, MD, Neha Korde, MD, Elisabet E. Manasanch, MD, Aaron W. Flanders, MD, Irina Maric, MD, Katherine R Calvo, MD, PhD, Adriana Zingone, MD, PhD, Rene Costello, MS, Daniel Cordaro, MD, Audrey Sato, MD, Marcia Mulquin, RN, Diamond Zuchlinski, RN, Mark Roschewski, MD, Ola Landgren, M.D., Ph.D.
Journal: Blood
Blood (2012) 120 (21): 4006.
https://doi.org/10.1182/blood.V120.21.4006.4006
Published: 2012